Metropolis Healthcare Ltd. · NSE:METROPOLIS

Metropolis Healthcare — Q2 FY27 Earnings Presentation

22 slides from Metropolis Healthcare's earnings presentation, Nov 3, 2026

  1. Slide 1: Exchange filing cover letter for investor presentation

    Ref: MHL/Sec&Legal/2026-27/57 November 03, 2026 To, BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we ar

  2. Slide 2: Q2 & H1FY27 Investor Presentation

    Q2 & H1FY27 Investor Presentation 1

  3. Slide 3: Safe Harbor

    Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been Certain matters discussed in this Presentation may contain statements regarding the prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely Company’s market opportunity and bu

  4. Slide 4: H1 FY27: Delivery Ahead Of Guidance

    H1 FY27 Delivery Ahead Of Guidance REVENUE EBITDA PAT INR 947 Cr INR 248 Cr INR 132 Cr 16% YoY 25% YoY 35% YoY EBITDA MARGIN PAT MARGIN 26.2% 14.0% 190 bps 200 bps ● Sustained demand momentum and increasing ● H1FY27 EBITDA grew by 190 bps driven by, ● Mid-teen revenue growth delivered despite no thr

  5. Slide 5: Q2 FY27: Consistent Delivery Over Last Quarters

    Q2 FY27 Consistent Delivery Over Last 4 Quarters REVENUE EBITDA PAT INR 497 Cr INR 135 Cr INR 75 Cr 16% YoY 24% YoY 43% YoY EBITDA MARGIN PAT MARGIN 27.2% 15.2% 180 bps 290 bps ● Growth driven by volume and favourable mix, ● Q2FY27 EBITDA grew by 180 bps driven by ● Growth in patient and test volume

  6. Slide 6: Key Performance Indicators: Strong broad-based performance

    Q2 FY27 Key Performance Indicators: Strong broad-based performance Share of revenue by segment, Q2FY27 B2C REVENUE B2B REVENUE INR 289 Cr INR 208 Cr 18% Specialty INR 198 Cr) ▲ 17% YoY ▲ 15% YoY 40% TruHealth INR 86 Cr) 25% Semi-specialty Routine 17% PAT I E N T VO L U M E T E S T VO L U M E 4.07

  7. Slide 7: B2C revenue up 17% YoY & B2B revenue up 15% YoY

    Q2 FY27 · CHANNEL MIX B2C revenue up 17% YoY & B2B revenue up 15% YoY B2C · 58% B2B · 42% B2C 17% YoY B2B 15% YoY Owned and Franchise centers (urban and rural) B2B labs, hospitals, government, corporate & clinical trials TruHealth Growth Specialty Growth TruHealth Growth Specialty Growth 21% 23%

  8. Slide 8: TruHealth & Specialty: Strategic Growth Engines Outperforming

    Q2 FY27 · REVENUE GROWTH TruHealth & Specialty : Strategic Growth Engines Outperforming TruHealth Specialty Strong revenue momentum, premium mix & digital acceleration GROWT H CON T RI BU T I ON GROWT H CON T RI BU T I ON 20% 17% 20% 40% • Volume growth led by Tier 3 and • rural markets. • Diet and

  9. Slide 9: Diversified revenue contribution across geographies

    Q2 FY27 · REACH Diversified revenue contribution across geographies By Region By City Tier West 51% Tier I 66% 750 South 27% Tier II 8% North 17% Tier III 26% East 6% Region Growth Tier Growth West 16% Tier I 13% South 16% Tier II 14% 20% North 12% Tier III 20% East 13% Revenue contribution of dom

  10. Slide 10: Building a scalable, productive network

    INFRASTRUCTURE Building a scalable, productive network Laboratory Network Service Network 213 5,119 210 212 5,026 199 4,536 175 4,150 3,675 161 3,134 FY22 FY23 FY24 FY25 FY26 H1FY27 FY22 FY23 FY24 FY25 FY26 H1FY27 Over the last 5 years 52 labs added to the network. Over the last 5 years 1,985 servic

  11. Slide 11: Consolidated Profit & Loss Statement

    Q2 FY27 Consolidated Profit & Loss Statement Profit & Loss Statement Rs. Crs.) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Revenue from Operations 496.8 429.2 15.8% 947.0 815.3 16.2% Costs 361.9 320.3 698.9 617.2 Reported EBIDTA 134.9 108.9 23.9% 248.2 198.0 25.3% Reported EBIDTA % 27.2% 25.4% 180 bp

  12. Slide 12: Balance Sheet Overview

    H1FY27 Balance Sheet Overview Equity & Liabilities Rs. Crs.) Sep-26 Mar-26 Assets Rs. Crs.) Sep-26 Mar-26 Equity 1653.3 1524.6 Non-current Assets 1704.4 1669.4 Equity Share Capital 41.5 41.5 Property, Plant and Equipment 222.0 215.3 Other Equity 1600.0 1471.7 ROU Assets 230.2 194.7 Non-Controlling

  13. Slide 13: Metropolis 3.0

    STRATEGY Metropolis 3.0 The next phase of profitable, science-led growth — strengthening the core, expanding into adjacencies, and building lasting shareholder value.

  14. Slide 14: The Indian diagnostics industry

    MARKET CONTEXT The Indian diagnostics industry Market size — US$ bn 11% CAGR to 2034E 28.5 ~US$11 bn ~11% 21.0 India diagnostic labs market size, 2025 Projected CAGR, 20252034E 15.1 11.0 ~15% >60% 2025 2028E 2031E 2034E Organised chains’ share — rest is Share of mortality from non- fragmented co

  15. Slide 15: Key pillars of the strategy - poised to grow further

    METROPOLIS 3.0 Key pillars of the strategy - poised to grow further 1 2 Leading with Technology Differentiate Scientifically Pioneer AI and digital innovation to Lead with scientific excellence and redefine diagnostics and elevate uncompromising diagnostic quality, customer experience, building on o

  16. Slide 16: Driving business growth through digital transformation

    TECHNOLOGY Driving business growth through digital transformation THE TECHNOLOGY STACK A UNIQUE HEALTHCARE TECHNOLOGY STACK DELIVERS Enhanced Productivity Second-generation Point of Sale platform — Registration & Invoicing Platform 2.0. Efficient Patient Personalization Registration Rapid Scalabilit

  17. Slide 17: Scientifically driven, with a strong focus on quality

    SCIENCE · RESEARCH · ACADEMICS Scientifically driven, with a strong focus on quality 43 347 99% 99.99% 100% new tests added in H1FY27 tests added in FY26 including EQAS external quality report accuracy labs under CAP / NABL / (incl. CDP integrating Core menu assurance score KENAS or benchmarked Sci

  18. Slide 18: Metropolis ESG goals & key plans

    SUSTAINABILITY Metropolis ESG goals & key plans E Emissions for a greener tomorrow S Quality, safety, diversity & well-being G Integrity, security & compliance • Net Zero Scope 1 and 2) by FY43 • B2C NPS above 90 by FY28 • Zero data breaches • 45% lower GHG emissions intensity and 50% • 100% OHS aw

  19. Slide 19: CSR at Metropolis — creating a positive impact

    CORPORATE SOCIAL RESPONSIBILITY CSR at Metropolis — creating a positive impact ADOLESCENT REPRODUCTIVE MEDENGAGE PREVENTIVE HEALTHCARE SEXUAL HEALTH (ARSH) Preventive Healthcare Empowering Adolescents with Health and Life Nurturing young medical talent Strengthening Community Health Skills • 409 ben

  20. Slide 20: A dynamic leadership team for the next level of growth

    ‘PROMOTER LED — PROFESSIONALLY DRIVEN’ A dynamic leadership team for the next level of growth Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Founder & Non – Executive Promoter & Executive Chairperson Managing Director Non - Independent Director Dynamic Leadership Team for Next Level of Growth Sa

  21. Slide 21: Recent awards & accolades

    RECOGNITION Recent awards & accolades Oct’26 Sep’26 Sep’26 Ameera Shah – Most Powerful Women Surendran Chemmenkotil – India’s National Winner – Diagnostics Chain of in Business by Business Today, 2026 Impactful Healthcare Leaders 2026, ET the Year Award, by ET Healthworld Edge Times Group) Excellen

  22. Slide 22: Thank You

    Thank You F OR F U RTH E R IN F ORM ATION Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN  L73100MH2000PLC192798 CIN  U74140MH2010PTC204285 Mr. Kamlesh Kulkarni - Head, Legal & Mr. Sagar Shroff / Mr. Shogun Jain Secretarial 91 98205 19303 / 91 77383 77756 secretarial@metropoli

Metropolis Healthcare — Q2 FY27 Earnings Presentation on 6ix